Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 11/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | MPC2 | O95563 | 2/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086147 | 0.92 | MEN1 (0.52) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9631327 | 0.92 | MEN1 (0.54) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL10640416 | 0.91 | MEN1 (0.49) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL6708147 | 0.89 | MEN1 (0.55) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9532951 | 0.89 | MEN1 (0.58) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL8897536 | 0.89 | MEN1 (0.51) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9632731 | 0.88 | MEN1 (0.49) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL10641731 | 0.88 | PPARG (0.49) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9632720 | 0.88 | MEN1 (0.52) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9632761 | 0.88 | MEN1 (0.48) | MEN1MAPTKMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | claimed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | claimed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | claimed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | claimed |
| EP-0439321-B1 | Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use | SANKYO CO (JP) | 1995-03-15 | — | — | EP | claimed |
| EP-0439321-A2 | Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use | Sankyo Company Limited (JP) | 1991-07-31 | — | — | EP | claimed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | disclosed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| US-5614542-A | OBESITY RELATED, IMPROVING INSULIN RESISTANCE | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0439321-B1 | Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use | SANKYO CO (JP) | 1995-03-15 | — | — | EP | disclosed |
| EP-0439321-A2 | Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use | Sankyo Company Limited (JP) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | MEN1 3687/4885MAPT 9/4885KMT2A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.